{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hyper-IgM+Syndrome&page=2",
    "query": {
      "condition": "Hyper-IgM Syndrome",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hyper-IgM+Syndrome&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:08:35.068Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00006054",
      "title": "Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Immunologic Deficiency Syndromes",
        "Chediak-Higashi Syndrome",
        "Common Variable Immunodeficiency",
        "Graft Versus Host Disease",
        "X-Linked Lymphoproliferative Syndrome",
        "Familial Erythrophagocytic Lymphohistiocytosis",
        "Hemophagocytic Lymphohistiocytosis",
        "X-linked Agammaglobulinemia",
        "Wiskott-Aldrich Syndrome",
        "Chronic Granulomatous Disease",
        "X-linked Hyper IgM Syndrome",
        "Severe Combined Immunodeficiency",
        "Leukocyte Adhesion Deficiency Syndrome",
        "Virus-Associated Hemophagocytic Syndrome"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic Bone Marrow Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Fairview University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "Up to 35 Years"
      },
      "enrollment_count": null,
      "start_date": "2000-03",
      "completion_date": "2002-12",
      "has_results": false,
      "last_update_posted_date": "2009-10-15",
      "last_synced_at": "2026-05-22T03:08:35.068Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006054"
    },
    {
      "nct_id": "NCT00058799",
      "title": "Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Dose Level 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose Level 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose Level 3",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 11,
      "start_date": "1999-06",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2020-01-21",
      "last_synced_at": "2026-05-22T03:08:35.068Z",
      "location_count": 3,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00058799"
    },
    {
      "nct_id": "NCT06305286",
      "title": "Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 70,
      "start_date": "2024-03-04",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-05-22T03:08:35.068Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06305286"
    },
    {
      "nct_id": "NCT00006319",
      "title": "Molecular and Clinical Studies of Primary Immunodeficiency Diseases",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Wiskott- Aldrich Syndrome",
        "ADA Deficient SCID"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 266,
      "start_date": "2000-10-25",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-05-22T03:08:35.068Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006319"
    },
    {
      "nct_id": "NCT00058786",
      "title": "Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic B-Leukemia"
      ],
      "interventions": [
        {
          "name": "Injection of IL-2-secreting CD40L-expressing autologous B-CLL cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2002-12",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2012-05-23",
      "last_synced_at": "2026-05-22T03:08:35.068Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00058786"
    },
    {
      "nct_id": "NCT01884311",
      "title": "Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immune Deficiency Disorders",
        "Common Variable Immunodeficiency",
        "X-linked Agammaglobulinaemia",
        "Hyperimmunoglobulin M Syndrome"
      ],
      "interventions": [
        {
          "name": "Subgam",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bio Products Laboratory",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "2 Years to 75 Years"
      },
      "enrollment_count": 38,
      "start_date": "2015-08-20",
      "completion_date": "2017-05-25",
      "has_results": true,
      "last_update_posted_date": "2018-09-12",
      "last_synced_at": "2026-05-22T03:08:35.068Z",
      "location_count": 16,
      "location_summary": "Chandler, Arizona • Irvine, California • San Diego, California + 12 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01884311"
    },
    {
      "nct_id": "NCT00078520",
      "title": "Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Leukemia, B-Cell, Chronic"
      ],
      "interventions": [
        {
          "name": "Dose Level 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose Level 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose Level 2- Fixed Dose",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2003-01",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2020-01-21",
      "last_synced_at": "2026-05-22T03:08:35.068Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00078520"
    },
    {
      "nct_id": "NCT01646411",
      "title": "300 Antibody Diagnostic Test Kit",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Bacterial Infections",
        "Acute Viral Infections"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "The Plasma Source",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 300,
      "start_date": "2012-08",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2012-07-20",
      "last_synced_at": "2026-05-22T03:08:35.068Z",
      "location_count": 1,
      "location_summary": "Southampton, Pennsylvania",
      "locations": [
        {
          "city": "Southampton",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01646411"
    },
    {
      "nct_id": "NCT01289847",
      "title": "A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Primary Immune Deficiency Disorders",
        "Common Variable Immunodeficiency",
        "X-linked Agammaglobulinemia",
        "Hyper-IgM Syndrome",
        "Wiskott-Aldrich Syndrome"
      ],
      "interventions": [
        {
          "name": "Gammaplex",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bio Products Laboratory",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "2 Years to 16 Years"
      },
      "enrollment_count": 25,
      "start_date": "2011-03",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2014-12-23",
      "last_synced_at": "2026-05-22T03:08:35.068Z",
      "location_count": 8,
      "location_summary": "Irvine, California • Los Angeles, California • Centennial, Colorado + 5 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01289847"
    },
    {
      "nct_id": "NCT01652092",
      "title": "Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "SCID",
        "Omenn's Syndrome",
        "Reticular Dysgenesis",
        "Wiskott-Aldrich Syndrome",
        "Bare Lymphocyte Syndrome",
        "Common Variable Immunodeficiency",
        "Chronic Granulomatous Disease",
        "CD40 Ligand Deficiency",
        "Hyper IgM Syndrome",
        "X-linked Lymphoproliferative Disease",
        "Hemophagocytic Lymphohistiocytosis",
        "Griscelli Syndrome",
        "Chediak-Higashi Syndrome",
        "Langerhan's Cell Histiocytosis"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab 0.3 mg",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Transplantation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine phosphate 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab 0.2 mg",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine phosphate 30 mg",
          "type": "DRUG"
        },
        {
          "name": "MESNA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "Up to 50 Years"
      },
      "enrollment_count": 57,
      "start_date": "2012-09-04",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-15",
      "last_synced_at": "2026-05-22T03:08:35.068Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01652092"
    }
  ]
}